Rapport Therapeutics Target Price

See Rapport Therapeutics's analyst price targets ($60) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$42.44

Average Target Price

$59.75

40.8% upside

4 analysts in the last 4 months

High: $66 | Low: $52

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-06-24	Leerink Partners	$52	22.5% upside
2026-05-21	BTIG	$65	53.2% upside
2026-05-18	Truist Financial	$56	32% upside
2026-04-10	Raymond JamesTiago Fauth	$66	55.5% upside
2026-03-09	BTIGKambiz Yazdi	$47	10.7% upside
2026-02-02	Wells FargoBenjamin Burnett	$43	1.3% upside
2025-12-19	Wells Fargo	$51	20.2% upside
2025-12-09	H.C. WainwrightDouglas Tsao	$40	5.7% downside
2025-09-16	Truist FinancialJoon Lee	$44	3.7% upside
2024-07-02	JefferiesAndrew Tsai	$35	17.5% downside
2024-07-02	Stifel NicolausPaul Matteis	$35	17.5% downside

Rapport Therapeutics (RAPP) FAQ

The latest target price for RAPP is $60. Investors often review this figure alongside Rapport Therapeutics's historical trend and sector peers before judging valuation or financial health.

Rapport Therapeutics trades near $42.44 while the consensus target sits at $60 (40.8% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting RAPP's target price ($60), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.